Endothelial dysfunction-An obstacle of therapeutic angiogenesis

Ageing Research Reviews

Volumn 8, Issue 4, 2009, Pages 306-313

  Sun, Lan ^a   Bai, Yongyi ^b   Du, Guanhua ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b Sino German Laboratory for Molecular Medicine   (China)

Author keywords

Angiogenic factors; Endothelial dysfunction; Endothelial progenitor cells; Therapeutic angiogenesis

Indexed keywords

ADENOVIRUS VECTOR; ARGININE; BASIC FIBROBLAST GROWTH FACTOR; PLACEBO; PLASMID DNA; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT VASCULOTROPIN; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165;

ANGIOGENESIS; ANGIOGENIC GENE THERAPY; ARTERY DISEASE; CELL MIGRATION; CELL PROLIFERATION; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; ISCHEMIC HEART DISEASE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LOW DRUG DOSE; NONHUMAN; PERIPHERAL VASCULAR DISEASE; SHORT SURVEY; STEM CELL;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ANIMALS, LABORATORY; CLINICAL TRIALS AS TOPIC; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; GENE THERAPY; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; TREATMENT FAILURE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA;

EID: 69249205459     PISSN: 15681637     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arr.2009.04.003     Document Type: Short Survey

References (63)

1. Adams M.R., Jessup W., and Celermajer D.S. Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral l-arginine but not vitamin C. J. Am. Coll. Cardiol. 1 29 (3) (1997) 491-497
2. Al Sabti H. Therapeutic angiogenesis in cardiovascular disease. J. Cardiothorac. Surg. 2 (2007) 49
3. Auguste P., Javerzat S., and Bikfalvi A. Regulation of vascular development by fibroblast growth factors. Cell Tissue Res. 314 1 (2003) 157-166
4. Bai Y., Sun L., Yang T., Sun K., Chen J., and Hui R. Increase in fasting vascular endothelial function after short-term oral l-arginine is effective when baseline flow-mediated dilation is low: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 89 1 (2009) 77-84
5. Banai S., Jaklitsch M.T., Shou M., Lazarous D.F., Scheinowitz M., Biro S., Epstein S.E., and Unger E.F. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89 5 (1994) 2183-2189
6. Barac A., Campia U., and Panza J.A. Methods for evaluating endothelial function in humans. Hypertension 49 (2007) 748
7. Battler A., Scheinowitz M., Bor A., Hasdai D., Vered Z., Di Segni E., Varda-Bloom N., Nass D., Engelberg S., Eldar M., et al. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J. Am. Coll. Cardiol. 22 7 (1993) 2001-2006
8. Beeres S.L., Bax J.J., Kaandorp T.A., Zeppenfeld K., Lamb H.J., Dibbets-Schneider P., Stokkel M.P., Fibbe W.E., de Roos A., van der Wall E.E., Schalij M.J., and Atsma D.E. Usefulness of intramyocardial injection of autologous bone marrow-derived mononuclear cells in patients with severe angina pectoris and stress-induced myocardial ischemia. Am. J. Cardiol. 97 9 (2006) 1326-1331
9. Böger R.H. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "l-arginine paradox" and acts as a novel cardiovascular risk factor. J. Nutr. 134 (2004) 2842S-2847S
10. Bonetti P.O., Holmes Jr. D.R., Lerman A., and Barsness G.W. Enhanced external counterpulsation for ischemic heart disease. What's behind the curtain?. J. Am. Coll. Cardiol. 41 (2003) 1918-1925
11. Briguori C., Reimers B., Sarais C., Napodano M., Pascotto P., Azzarello G., Bregni M., Porcellini A., Vinante O., Zanco P., Peschle C., Condorelli G., and Colombo A. Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina. Am. Heart J. 151 3 (2006) 674-680
12. Caplice N.M. The future of cell therapy for acute myocardial infarction. Nat. Clin. Pract. Cardiovasc. Med. Suppl. 1 (2006) S129-S132
13. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6 (2000) 389-395
14. Dandona P., Ghanim H., Chaudhuri A., and Mohanty P. Thiazolidinediones-improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes. J. Diabetes Complications 22 1 (2008) 62-75
15. Davidson M.H. Clinical significance of statin pleiotropic effects. Hypotheses versus evidence. Circulation 111 (2005) 2280-2281
16. Erbs S., Linke A., Adams V., Lenk K., Thiele H., Diederich K.W., Emmrich F., Kluge R., Kendziorra K., Sabri O., Schuler G., and Hambrecht R. Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: first randomized and placebocontrolled study. Circ. Res. 97 8 (2005) 756-762
17. Folkman J., and D'Amore P.A. Blood vessel formation: what is its molecular basis?. Cell 87 (1996) 1153-1155
18. Gerhardt H., and Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res. 314 (2003) 15-23
19. Green D.J., Maiorana A., O'Driscoll G., and Taylor R. Effect of exercise training on endothelium-derived nitric oxide function in humans. J. Physiol. 561 (2004) 1-25
20. Grines C.L., Watkins M.W., Mahmarian J.J., Iskandrian A.E., Rade J.J., Marrott P., Pratt C., Kleiman N, and Angiogene GENe Therapy (AGENT-2) Study Group. A randomized, double-blind, placebocontrolled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J. Am. Coll. Cardiol. 42 (2003) 1339-1347
21. Harada K., Friedman M., Lopez J.J., Wang S.Y., Li J., Prasad P.V., Pearlman J.D., Edelman E.R., Sellke F.W., and Simons M. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am. J. Physiol. 270 5 Pt 2 (1996) H1791-H1802
22. Hedman M., Hartikainen J., Syvänne M., Stjernvall J., Hedman A., Kivelä A., Vanninen E., Mussalo H., Kauppila E., Simula S., et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107 (2003) 2677-2683
23. Henry T.D. Science, medicine, and the future. Therapeutic angiogenesis. BMJ 318 June (7197) (1999) 1536-1539
24. Henry T.D., Annex B.H., McKendall G.R., Azrin M.A., Lopez J.J., Giordano F.J., Shah P.K., Willerson J.T., Benza R.L., Berman D.S., Gibson C.M., Bajamonde A., Rundle A.C., Fine J., McCluskey E.R., and VIVA Investigators. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 107 (2003) 1359-1365
25. Henry T.D., Grines C.L., Watkins M.W., Dib N., Barbeau G., Moreadith R., Andrasfay T., and Engler R.L. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J. Am. Coll. Cardiol. 50 11 (2007) 1038-1046
26. Jacobs J. Combating cardiovascular disease with angiogenic therapy. Drug Discov. Today 12 23-24 (2007) 1040-1045
27. Kajiguchi M., Kondo T., Izawa H., Kobayashi M., Yamamoto K., Shintani S., Numaguchi Y., Naoe T., Takamatsu J., Komori K., and Murohara T. Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circ. J. 71 2 (2007) 196-201
28. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer. 3 6 (2003) 422-433
29. Kang H.J., Kim H.S., Zhang S.Y., Park K.W., Cho H.J., Koo B.K., Kim Y.J., Soo Lee D., Sohn D.W., Han K.S., et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 363 (2004) 751-756
30. Kastrup J., Jørgensen E., Rück A., Tägil K., Glogar D., Ruzyllo W., Bøtker H.E., Dudek D., Drvota V., Hesse B., Thuesen L., Blomberg P., Gyöngyösi M., Sylvén C., and Euroinject One Group. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris. A randomized double-blind placebo-controlled study: the Euroinject One trial. J. Am. Coll. Cardiol. 45 (2005) 982-988
31. Khurana R., and Simons M. Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease. Trends Cardiovasc. Med. 13 3 (2003) 116-122
32. Koifman B., Topilski I., Megidish R., Zelmanovich L., Chernihovsky T., Bykhovsy E., and Keren G. Effects of losartan 1 l-arginine on nitric oxide production, endothelial cell function, and hemodynamic variables in patients with heart failure secondary to coronary heart disease. Am. J. Cardiol. 98 (2006) 172-177
33. Lederman R.J., Mendelsohn F.O., Anderson R.D., Saucedo J.F., Tenaglia A.N., Hermiller J.B., Hillegass W.B., Rocha-Singh K., Moon T.E., Whitehouse M.J., Annex B.H., and TRAFFIC Investigators. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 359 (2002) 2053-2058
34. Lekakis J.P., Papathanassiou S., Papaioannou T.G., Papamichael C.M., Zakopoulos N., Kotsis V., Dagre A.G., Stamatelopoulos K., Protogerou A., and Stamatelopoulos S.F. Oral l-arginine improves endothelial dysfunction in patients with essential hypertension. Int. J. Cardiol. 86 (2002) 317-323
35. Lerman A., Burnett Jr. J.C., Higano S.T., McKinley L.J., and Holmes Jr. D.R. Long-term l-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 97 (1998) 2123-2128
36. Lipscombe L.L. Thiazolidinediones: do harms outweigh benefits?. CMAJ 180 1 (2009) 16-17
37. Mack C.A., Patel S.R., Schwarz E.A., Zanzonico P., Hahn R.T., Ilercil A., Devereux R.B., Goldsmith S.J., Christian T.F., Sanborn T.A., Kovesdi I., Hackett N., Isom O.W., Crystal R.G., and Rosengart T.K. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J. Thorac. Cardiovasc. Surg. 115 1 (1998) 176-177 168-76; discussion
38. Matsumoto T., and Claesson-Welsh L. VEGF receptor signal transduction. Sci. STKE 112 (2001) RE21
39. Moulton K., and Folkman J. In: Chien K. (Ed). Molecular Basis of Cardiovascular Disease (1998), Saunders WB 93-409
40. Münzel T., Sinning C., Post F., Warnholtz A., and Schulz E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann. Med. 40 (2008) 180-196
41. Ornitz D.M., and Itoh N. Fibroblast growth factors. Genome Biol. 2 3 (2001) reviews 3005.1-3005.12
42. Pandya N.M., Dhalla N.S., and Santani D.D. Angiogenesis-a new target for future therapy. Vascul. Pharmacol. 44 5 (2006) 265-274
43. Payne T.R., Oshima H., Okada M., Momoi N., Tobita K., Keller B.B., Peng H., and Huard J. A relationship between vascular endothelial growth factor, angiogenesis, and cardiac repair after muscle stem cell transplantation into ischemic hearts. J. Am. Coll. Cardiol. 50 17 (2007) 1677-1684
44. Rajagopalan S., Mohler III E., Lederman R.J., Saucedo J., Mendelsohn F.O., Olin J., Blebea J., Goldman C., Trachtenberg J.D., Pressler M., Rasmussen H., Annex B.H., and Hirsch A.T. Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE trial. Am. Heart J. 145 (2003) 1114-1118
45. Rajagopalan S., Mohler III E.R., Lederman R.J., Mendelsohn F.O., Saucedo J.F., Goldman C.K., Blebea J., Macko J., Kessler P.D., Rasmussen H.S., and Annex B.H. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108 (2003) 1933-1938
46. Tio R.A., Tkebuchava T., Scheuermann T.H., Lebherz C., Magner M., Kearny M., Esakof D.D., Isner J.M., and Symes J.F. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium. Hum. Gene Ther. 10 18 (1999) 2953-2960
47. Ruan W., Pan C.Z., Huang G.Q., Li Y.L., Ge J.B., and Shu X.H. Assessment of left ventricular segmental function after autologous bone marrow stem cells transplantation in patients with acute myocardial infarction by tissue tracking and strain imaging. Chin. Med. J. (Engl.) 118 14 (2005) 1175-1181
48. Ruel M., Beanlands R.S., Lortie M., Chan V., Camack N., deKemp R.A., Suuronen E.J., Rubens F.D., DaSilva J.N., Sellke F.W., Stewart D.J., and Mesana T.G. Concomitant treatment with oral l-arginine improves the efficacy of surgical angiogenesis in patients with severe diffuse coronary artery disease: the Endothelial Modulation In Angiogenic Therapy randomized controlled trial. J. Thorac. Cardiovasc. Surg. 135 4 (2008) 762
49. Schächinger V., Erbs S., Elsässer A., Haberbosch W., Hambrecht R., Hölschermann H., Yu J., Corti R., Mathey D.G., Hamm C.W., Süselbeck T., Assmus B., Tonn T., Dimmeler S., Zeiher A.M., and REPAIR-AMI Investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 355 12 (2006) 1210-1221
50. Schlaudraff K., Schumacher B., von Specht B.U., Seitelberger R., Schlosser V., and Fasol R. Growth of "new" coronary vascular structures by angiogenetic growth factors. Eur. J. Cardiothorac. Surg. 7 12 (1993) 637-643
51. Ylä-Herttuala S., Markkanen J.E., and Rissanen T.T. Gene therapy for ischemic cardiovascular diseases: some lessons learned from the first clinical trials. Trends Cardiovas. Med. 14 8 (2004) 295-300
52. Simons M., Annex B.H., Laham R.J., Kleiman N., Henry T., Dauerman H., Udelson J.E., Gervino E.V., Pike M., Whitehouse M.J., Moon T., and Chronos N.A. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 105 (2002) 788-793
53. Solomon A.J., and Gersh B.J. Management of chronic stable angina: medical therapy, percutaneous transluminal coronary angioplasty, and coronary artery bypass graft surgery: lessons from the randomized trials. Ann. Intern. Med. 128 3 (1998) 216-223
54. Stewart D.J., Hilton J.D., Arnold J.M., Gregoire J., Rivard A., Archer S.L., Charbonneau F., Cohen E., Curtis M., Buller C.E., Mendelsohn F.O., Dib N., Page P., Ducas J., Plante S., Sullivan J., Macko J., Rasmussen C., Kessler P.D., and Rasmussen H.S. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatment. Gene Ther. 13 (2006) 1503-1511
55. Strauer B.E., Brehm M., Zeus T., Bartsch T., Schannwell C., Antke C., Sorg R.V., Kögler G., Wernet P., Müller H.W., and Köstering M. Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT study. J. Am. Coll. Cardiol. 46 9 (2005) 1651-1658
56. Tousoulis D., Davies G.J., Tentolouris C., Crake T., Katsimaglis G., Stefanadis C., and Toutouzas P. Effects of changing the availability of the substrate for nitric oxide synthase by l-arginine administration on coronary vasomotor tone in angina patients with angiographically narrowed and in patients with normal coronary arteries. Am. J. Cardiol. 82 1110-3 (1998) A6
57. Unger E.F., Banai S., Shou M., Lazarous D.F., Jaklitsch M.T., Scheinowitz M., Correa R., Klingbeil C., and Epstein S.E. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am. J. Physiol. 266 April (4 Pt 2) (1994) H1588-H1595
58. Voisine P., Bianchi C., Khan T.A., Ruel M., Xu S.H., Feng J., Li J., Malik T., Rosinberg A., and Sellke F.W. Normalization of coronary microvascular reactivity and improvement in myocardial perfusion by surgical vascular endothelial growth factor therapy combined with oral supplementation of l-arginine in a porcine model of endothelial dysfunction. J. Thorac. Cardiovasc. Surg. 129 (2005) 1414-1420
59. Voisine P., Li J., Bianchi C., Khan T.A., Ruel M., Xu S.H., Feng J., Rosinberg A., Malik T., Nakai Y., and Sellke F.W. Effects of l-arginine on fibroblast growth factor 2-induced angiogenesis in a model of endothelial dysfunction. Circulation 112 (2005) I202-I207
60. Werner N., Priller J., Laufs U., Endres M., Bohm M., Dirnagl U., and Nickenig G. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1567-1572
61. Witte D.R., Westerink J., de Koning E.J., van der Graaf Y., Grobbee D.E., and Bots M.L. Is the association between flow-mediated dilation and cardiovascular risk limited to low-risk populations?. J. Am. Coll. Cardiol. 45 12 (2005) 1987-1993
62. Wollert K.C., Meyer G.P., Lotz J., Ringes-Lichtenberg S., Lippolt P., Breidenbach C., Fichtner S., Korte T., Hornig B., Messinger D., Arseniev L., Hertenstein B., Ganser A., and Drexler H. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364 9429 (2004) 141-148
63. Zachary I., and Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc. Res. 49 (2001) 568-581